{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:08:33Z","timestamp":1790114913288,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jpba.2026.117668","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:04:40Z","timestamp":1784934280000},"page":"117668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Implications of formulation change on the in-use stability of compounded pemetrexed infusion bags: Impact of excipients, solvent and storage conditions"],"prefix":"10.1016","volume":"281","author":[{"given":"Loup","family":"Nobilet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-3695","authenticated-orcid":false,"given":"Philippe-Henri","family":"Secretan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Solgadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroun","family":"Aouati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Combeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Antignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassane","family":"Sadou Yay\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117668_bib1","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2026.117668_bib2","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3816\/CLC.2004.s.003","article-title":"Pharmacology and mechanism of action of pemetrexed","volume":"5","author":"Adjei","year":"2004","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.jpba.2026.117668_bib3","unstructured":"B.U. Riebesehl, J. Kemken, Pharmaceutical composition, US6686365B2, 2004. https:\/\/patents.google.com\/patent\/US6686365B2\/en?q=(alimta)&oq=alimta (accessed June 10, 2026)."},{"key":"10.1016\/j.jpba.2026.117668_bib4","article-title":"ICH Q3B (R2) Impurities in new drug products - scientific guideline","author":"EMA","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.jpba.2026.117668_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpba.2014.11.032","article-title":"Development of a purity control strategy for pemetrexed disodium and validation of associated analytical methodology","volume":"105","author":"Warner","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117668_bib6","article-title":"A stability-indicating LC-MS\/MS method optimization for Pemetrexed through design of experiments: identification and characterization of major oxidative degradation product","volume":"183","author":"Narendan","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117668_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/pharmaceutics12010046","article-title":"Effect of formulation factors and oxygen levels on the stability of aqueous injectable solution containing pemetrexed","volume":"12","author":"Won","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2026.117668_bib8","unstructured":"Pemetrexed disodium 2-5 hydrated, Eur. Pharmacopoeia 112 (n.d.) 07\/2023:3046.."},{"key":"10.1016\/j.jpba.2026.117668_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trac.2013.06.005","article-title":"Tools and workflow for structure elucidation of drug degradation products","volume":"49","author":"Foti","year":"2013","journal-title":"TrAC. Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117668_bib10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.scitotenv.2017.12.182","article-title":"Pemetrexed degradation by photocatalytic process: kinetics, identification of transformation products and estimation of toxicity","volume":"624","author":"Secr\u00e9tan","year":"2018","journal-title":"Sci. Total. Environ."},{"key":"10.1016\/j.jpba.2026.117668_bib11","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.xphs.2016.06.029","article-title":"Determination of the degradation chemistry of the antitumor agent pemetrexed disodium","volume":"105","author":"Jansen","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117668_bib12","unstructured":"Pemetrexed for injection, US Pharmacopoeia (n.d.) M5161_05_01."},{"key":"10.1016\/j.jpba.2026.117668_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/10408347.2024.2384046","article-title":"Impurities in active pharmaceutical ingredients and drug products: a critical review","volume":"56","author":"Finotti Cordeiro","year":"2026","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117668_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/ijms25010180","article-title":"Mass spectrometry study about in vitro and in vivo reaction between metformin and glucose: a preliminary investigation on alternative biological behavior","volume":"25","author":"Bartolucci","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2026.117668_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1208\/s12249-016-0494-2","article-title":"Investigation of possible maillard reaction between acyclovir and dextrose upon dilution prior to parenteral administration","volume":"17","author":"Siahi Shadbad","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jpba.2026.117668_bib16","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3762\/bjoc.13.222","article-title":"Structural diversity in the host\u2013guest complexes of the antifolate pemetrexed with native cyclodextrins: gas phase, solution and solid state studies","volume":"13","author":"Ceborska","year":"2017","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.jpba.2026.117668_bib17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijpharm.2017.06.009","article-title":"Effects of cyclodextrins on the chemical stability of drugs","volume":"531","author":"Popielec","year":"2017","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:44:05Z","timestamp":1790113445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526003365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":17,"alternative-id":["S0731708526003365"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117668","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of formulation change on the in-use stability of compounded pemetrexed infusion bags: Impact of excipients, solvent and storage conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117668"}}